Foldamers are an emerging class of molecules with promising applications in drug discovery.
The UrelixTM approach consists of replacing a portion of a lead peptide with an oligourea segment to improve its pharmaceutical properties.
UrelixTM technologies were applied to GLP-1, an anti-diabetic peptide, to improve its action in vivo. See publication in Nature Communications here.
Do not hesitate to contact us if you think our technology
could be helpful for your projects.